Cover Image
市場調查報告書

腦膜炎:開發中產品分析

Meningitis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 363136
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
腦膜炎:開發中產品分析 Meningitis - Pipeline Review, H1 2017
出版日期: 2017年06月27日 內容資訊: 英文 54 Pages
簡介

本報告提供腦膜炎治療藥的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

腦膜炎概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

腦膜炎:企業開發中的治療藥

腦膜炎:大學/機關研究中的治療藥

腦膜炎:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

腦膜炎:企業開發中的產品

腦膜炎:大學/機關研究中的產品

腦膜炎治療藥的開發企業

  • Adenium Biotech ApS
  • Amplyx Pharmaceuticals, Inc.
  • Chiesi Farmaceutici SpA
  • ContraFect Corporation
  • Genticel S.A.
  • LG Life Science LTD.
  • Matinas BioPharma Holdings, Inc.
  • Sanofi Pasteur SA
  • Viamet Pharmaceuticals, Inc.

腦膜炎:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

腦膜炎:暫停中的計劃

腦膜炎:中止開發的產品

腦膜炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9447IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Meningitis - Pipeline Review, H1 2017, provides an overview of the Meningitis (Infectious Disease) pipeline landscape.

Meningitis is the inflammation caused by viruses and bacteria on the protective membranes covering the brain and spinal cord. The cause of inflammation can be infection by viruses, bacteria, or other microorganisms, and less commonly by certain drugs. As the inflammation is in proximity to the brain and spinal cord, meningitis can be life threatening.Viral meningitis is not life-threatening and the people affected with this can be cured and recover quickly, but bacterial meningitis is serious and life-threatening. There are three major bacteria which lead to bacterial meningitis. Neisseria meningitides are one of these, and causes meningococcal meningitis. Researchers have identified 13 major serogroups of N. meningitides, out of which the majority of cases are from one of five serogroups: A, B, C, Y and W-135. Drugs and vaccines are available to treat the serogroups AC, C, ACWY, and A. There are also vaccines available to prevent meningitis caused by serogroups A, C, Y, W-135. There are no vaccines or drugs available for the prevention and treatment of meningococcal meningitis caused by serogroup B. This represents a major unmet need in the market. Pneumococcal meningitis is another major bacterial cause of meningitis, caused by the bacteria streptococcus pneumonia, while haemophilius influenza is the third, and causes meningitis in infants. Approximatiely 44-46% cases of bacterial meningitis have all of the following three symptoms - severe headache, nuchal ridgidity ((inability to flex the neck forward passively due to increased neck muscle tone and stiffness) and altered mental status. Out of this triad of symptoms severe headache is the most common and occurs in 90% of the cases. If nove of the above mentioned symptoms are present, then occurrence of bacterial meningitis is least likely.Other clinical feature include photophobia (fear of bright light), phonophobia (fear of loud noises). In small children above symptoms are difficult to spot. Vague symptoms like irritability and unwell appearance are more common in them. In infants up to 6 months bulging of the fontanelle (soft spot on baby's head) may be visible. Other less severe illnesses like extreme cold, abnormality in skin color and leg pain may also be distinguishing features for meningitis.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Meningitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Meningitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Meningitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Meningitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 3, 3 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Meningitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Meningitis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Meningitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Meningitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Meningitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Meningitis (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Meningitis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Meningitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Meningitis - Overview
    • Meningitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Meningitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Meningitis - Companies Involved in Therapeutics Development
    • Chongqing Zhifei Biological Products Co Ltd
    • ContraFect Corp
    • Matinas BioPharma Holdings Inc
    • Viamet Pharmaceuticals Inc
  • Meningitis - Drug Profiles
    • (Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amphotericin B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CF-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CF-302 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CF-303 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CF-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CF-309 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EUC-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W135, X, Y] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pneumococcal [serotype 4, 6A] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Neuraminidase A for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target PknD for Tuberculous Meningitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VT-1129 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VY-OZ - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Meningitis - Dormant Projects
  • Meningitis - Discontinued Products
  • Meningitis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 02, 2017: Matinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis
      • May 30, 2017: Matinas BioPharma Announces Two Upcoming Data Presentations of Lead Product Candidate MAT2203 at The American Society for Microbiology's ASM Microbe 2017 Conference
      • Jun 16, 2016: Clinical Trial of Phase III of Group A and Group C Meningococcal Conjugate vaccine Phase III Clinical Trial Initiated
      • Jun 01, 2016: Viamet Receives Fast Track Designation from the FDA for VT-1129 for the Treatment of Cryptococcal Meningitis
      • Sep 16, 2015: FDA Grants QIDP Designation to VT-1129 for Treatment of Cryptococcal Meningitis
      • Jun 29, 2015: Olymvax obtains Chinese approval for clinical trials of Meningococcal conjugate vaccine
      • Apr 24, 2015: Viamet to Provide Update on VT-1129, Novel Antifungal Program at ECCMID 2015
      • Sep 11, 2014: Viamet Receives Orphan Drug Designation for VT-1129
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Meningitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Meningitis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2017
  • Meningitis - Pipeline by ContraFect Corp, H1 2017
  • Meningitis - Pipeline by Matinas BioPharma Holdings Inc, H1 2017
  • Meningitis - Pipeline by Viamet Pharmaceuticals Inc, H1 2017
  • Meningitis - Dormant Projects, H1 2017
  • Meningitis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Meningitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top